Wilson Disease
Conditions
Brief summary
A study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them for a further 12 months.
Detailed description
A retrospective study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them prospectively for a further 12 months.
Interventions
A retrospective review of patients' medical records
Sponsors
Univar BV
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 1 year to 90 years of age. * Physician established diagnosis of Wilson disease based on a Ferenci score \> 3. * Documented treatment with d-Penicillamine, withdrawal of treatment with d- Penicillamine, followed by treatment with trientine for at least 6 months at date of informed consent. * Able/willing to provide written informed consent. * For enrolment in the prospective part, enrolment in the retrospective part of the study is required.
Exclusion criteria
* Incomplete history of medication use for trientine from initial diagnosis to latest follow up. * Unavailable outcome data for hepatic and neurological course of disease at assessment time points. * Patients with acute liver failure and fulminant hepatic disease with fatal outcome. * Hypersensitivity to trientine and severe anaemia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical outcome specific to the retrospective part of the study | 48 months | The clinical course of neurological and hepatic disease for each available time point after initiation of treatment (6, 12, 24, 36, and 48 months, and at the last available time point while taking second line trientine) will be scored (Investigator's score) based on neurological and hepatic status at the time of initiating trientine as: 1 = Unchanged 2 = Improved but not normal 3 = Improved to normal 4 = Asymptomatic over duration of therapy 5 = Worsened. |
| Clinical outcome specific to the prospective part of the study | 12 months | The clinical course of neurological and hepatic disease will be scored (Investigator's score) based on the status at 6 and 12 months after Baseline as: 1 = Unchanged 2 = Improved but not normal 3 = Improved to normal 4 = Asymptomatic over duration of therapy 5 = Worsened A patient will be counted as a responder if they have a rating of ≤4 at the 12 month visit for both the neurological and hepatic Investigator's score. They will be counted as a non-responder if they have a rating = 5 for one or both scores at the 12 month visit or if they were discontinued from the study for any reason prior to the 12 month visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety Endpoint Applicable to both the Retrospective and Prospective Parts of the Study | Up to 60 months | All AEs related to trientine treatment, and AEs leading to discontinuation of trientine will be assessed at each available study time point. |
| Quality of Life Endpoints for the Prospective Part of the Study | 12 months | The QoL questionnaires will be completed for each time point and data will be compared to baseline (prospective part) after 6 and 12 months |
Countries
Germany, Greece, Italy, United Kingdom
Outcome results
None listed